Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations

Journal of Clinical Oncology

Volumn 24, Issue 12, 2006, Pages 1924-1931

  Thompson, Margaret C ^b   Fuller, Christine ^b   Hogg, Twala L ^b   Dalton, James ^b   Finkelstein, David ^b   Lau, Ching C ^b   Chintagumpala, Murali ^b   Adesina, Adekunle ^b   Ashley, David M ^b   Kellie, Stewart J ^b   Taylor, Michael D ^b   Curran, Tom ^b   Gajjar, Amar ^b   Gilbertson, Richard J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

SONIC HEDGEHOG PROTEIN; WNT1 PROTEIN; ANTINEOPLASTIC AGENT;

ACCURACY; ARTICLE; CHROMOSOME 6; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DNA FINGERPRINTING; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC DISORDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; ADOLESCENT; ADULT; CEREBELLUM TUMOR; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; GENE EXPRESSION PROFILING; GENETICS; GENOMICS; INFANT; MALE; NEWBORN; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATIENT SELECTION; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; INFANT, NEWBORN; MALE; MEDULLOBLASTOMA; PATIENT SELECTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33646362581     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.4974     Document Type: Article

References (39)

1. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
2. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
3. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
4. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
5. Kaiser J: National Institutes of Health: NCI gears up for Cancer Genome Project. Science 307: 1182a, 2005
6. Gabor Miklos GL: The Human Cancer Genome Project: One more misstep in the war on cancer. Nat Biotechnol 23:535-537, 2005
7. Parsons DW, Wang T-L, Samuels Y, et al: Colorectal cancer: Mutations in a signalling pathway. Nature 436:792, 2005
8. Stephens P, Edkins S, Davies H, et al: A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 37:590-592, 2005
9. Davies H, Hunter C, Smith R, et al: Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65:7591-7595, 2005
10. Bignell G, Smith R, Hunter C, et al: Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adolescents and adults. Genes Chromosomes Cancer 45:42-46, 2006
11. Hernan R, Fasheh R, Calabrese C, et al: ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 63:140-148, 2003
12. Taylor MD, Liu L, Raffel C, et al: Mutations in SUFU predispose to medulloblastoma. Nat Genet 31:306-310, 2002
13. Hahn H, Wicking C, Zaphiropoulous PG, et al: Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85:841-851, 1996
14. Satoh S, Daigo Y, Furukawa Y, et al: AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24:245-250, 2000
15. Huang H, Mahler-Araujo BM, Sankila A, et al: APC mutations in sporadic medulloblastomas. Am J Pathol 156:433-437, 2000
16. Burns AS, Jaros E, Cole M, et al: The molecular pathology of p53 in primitive neuroectodermal tumours of the central nervous system. Br J Cancer 86:1117-1123, 2002
17. MacDonald TJ, Brown KM, LaFleur B, et al: Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 29:143-152, 2001
18. Pomeroy SL, Tamayo P, Gaasenbeek M, et al: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415:436-442, 2002
19. Ellison DW, Clifford SC, Gajjar A, et al: What's new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol 7:53-66, 2003
20. Wolter M, Reifenberger J, Sommer C, et al: Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 57:2581-2585, 1997
21. Zurawel RH, Chiappa SA, Allen C, et al: Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res 58:896-899, 1998
22. Hallahan AR, Pritchard JI, Hansen S, et al: The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 64:7794-7800, 2004
23. Hallahan AR, Pritchard Jl, Chandraratna RA, et al: BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 9:1033-1038, 2003
24. Moon RT, Kohn AD, Ferrari GVD, et al: WNT and [beta]-catenin signaling: Diseases and therapies. Nat Rev Genet 5:691-701, 2004
25. Romer JT, Kimura H, Magdaleno S, et al: Suppression of the SHH pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/)p53(-/-) mice. Cancer Cell 6:229-240, 2004
26. Nickoloff BJ, Osborne BA, Miele L: Notch signaling as a therapeutic target in cancer: A new approach to the development of cell fate modifying agents. Oncogene 22:6598-6608, 2003
27. van de Wetering M, Sancho E, Verweij C, et al: The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111:241-250, 2002
28. Nelson WJ, Nusse R: Convergence of WNT, beta-catenin, and cadherin pathways. Science 303: 1483-1487, 2004
29. Schwartz DR, Wu R, Kardia SL, et al: Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res 63: 2913-2922, 2003
30. Eberhart CG, Tihan T, Burger PC: Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol 59:333-337, 2000
31. Lee Y, Miller HL, Jensen P, et al: A molecular fingerprint for medulloblastoma. Cancer Res 63: 5428-5437, 2003
32. Gilbertson RJ: Medulloblastoma: Signalling a change in treatment. Lancet Oncol 5:209-218, 2004
33. Wu G, Xu G, Schulman BA, et al: Structure of a beta-TrCP1-Skp1-beta- catenin complex: Destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol Cell 11:1445-1456, 2003
34. Reifenberger J, Wolter M, Weber RG, et al: Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 58:1798-1803, 1998
35. Strother D, Ashley D, Kellie SJ, et al: Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: Results of a collaborative study. J Clin Oncol 19:2696-2704, 2001
36. Taylor RE, Bailey CC, Robinson K, et al: Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 21:1581-1591, 2003
37. Zeltzer PM, Boyett JM, Finlay JL, et al: Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17:832-845, 1999
38. Zeller C, Hinzmann B, Seitz S, et al: SASH1: A candidate tumor suppressor gene on chromosome 6q24.3 is downregulated in breast cancer. Oncogene 22:2972-2983, 2003
39. Thomas GA, Raffel C: Loss of heterozygosity on 6q, 16q, and 17p in human central nervous system primitive neuroectodermal tumors. Cancer Res 51:639-643, 1991